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ARTICLE OPEN
A systematic review of feasibility studies promoting the use of
mobile technologies in clinical research
Jessie P. Bakker1, Jennifer C. Goldsack2,3,4, Michael Clarke5, Andrea Coravos 3,6,7, Cynthia Geoghegan8, Alan Godfrey 9,
Matthew G. Heasley 10, Daniel R. Karlin3,11, Christine Manta12, Barry Peterson13, Ernesto Ramirez 14, Nirav Sheth15, Antonia Bruno16,
Emilia Bullis17, Kirsten Wareham18, Noah Zimmerman 19, Annemarie Forrest2 and William A. Wood20
Mobile technologies, such as smart phone applications, wearables, ingestibles, and implantables, are increasingly used in clinical
research to capture study endpoints. On behalf of the Clinical Trials Transformation Initiative, we aimed to conduct a systematic
scoping review and compile a database summarizing pilot studies addressing mobile technology sensor performance, algorithm
development, software performance, and/or operational feasibility, in order to provide a resource for guiding decisions about which
technology is most suitable for a particular trial. Our systematic search identiﬁed 275 publications meeting inclusion criteria. From
these papers, we extracted data including the medical condition, concept of interest captured by the mobile technology, outcomes
captured by the digital measurement, and details regarding the sensors, algorithms, and study sample. Sixty-seven percent of the
technologies identiﬁed were wearable sensors, with the remainder including tablets, smartphones, implanted sensors, and cameras.
We noted substantial variability in terms of reporting completeness and terminology used. The data have been compiled into an
online database maintained by the Clinical Trials Transformation Initiative that can be ﬁltered and searched electronically, enabling
a user to ﬁnd information most relevant to their work. Our long-term goal is to maintain and update the online database, in order to
promote standardization of methods and reporting, encourage collaboration, and avoid redundant studies, thereby contributing to
the design and implementation of efﬁcient, high-quality trials.
npj Digital Medicine            (2019) 2:47 ; https://doi.org/10.1038/s41746-019-0125-x
INTRODUCTION
An increasing number of clinical trials are being designed in which
mobile technology—including smart phone applications, wear-
ables, ingestibles, implantables, and other mobile platforms
containing sensors—are being used to capture data of interest
to trial stakeholders.1–4 Rapidly evolving technology within the
last several years has allowed for more powerful algorithms
(software) to convert the data that are detected by the sensors
(hardware) into clinically meaningful endpoints (outcomes).5 For
example, technology worn at the wrist might include an
accelerometer, and various algorithms may then be applied to
the acceleration signal to generate estimates of total sleep time,
steps per day, and other endpoints. In addition to digitizing
existing endpoints, mobile technologies can be used to develop
novel endpoints.
Potential advantages of trials that adopt mobile endpoints
include: real-time data capture and analytics; less frequent study
visits; the ability to capture day-to-day variability by collecting
data continuously; the availability of objective endpoints to
complement patient- and clinician-reported outcomes; increased
measurement precision and therefore smaller samples; and the
ability to collect data that are more likely to reﬂect habitual, real-
world experiences of trial participants.6–8
Although mobile endpoint collection may have several
potential advantages, guidance is needed, such as the new
framework issued by the U.S. Food and Drug Administration (FDA)
to promote development of digital tools (https://www.fda.gov/
NewsEvents/Newsroom/FDAInBrief/ucm626166.htm) for investi-
gators to make decisions about which technology is most suitable
for a particular trial, and what methodology ensures trials are
conducted as efﬁciently as possible.9,10 The Clinical Trials
Transformation Initiative (CTTI), a public-private partnership co-
founded by Duke University and the FDA, has recently issued four
sets of recommendations and resources intended as a compre-
hensive guide to improving clinical trial quality and efﬁciency
through appropriate use of mobile technology. Topics covered
include the development of novel endpoints; design and
implementation of decentralized trials; the application of mobile
technology in clinical trials; and the optimization of mobile clinical
trials by engaging patients and sites (https://www.ctti-clinicaltrials.
org/programs/mobile-clinical-trials). One strong CTTI Mobile Tech-
nology recommendation is for investigators to conduct small
feasibility/pilot studies before launching a clinical trial, with the
overall aim of reducing risk by assessing sensor accuracy,
developing and/or validating algorithms, optimizing data quality,
identifying unanticipated challenges, exposing weaknesses of the
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selected system, enhancing participant experience, and satisfying
user engagement. To catalog the breadth of feasibility studies and
facilitate the use of these data to enable the development of
clinical trials that will use mobile technologies, we conducted a
systematic scoping review of the literature, with the overall goal of
compiling a living database of feasibility studies. In doing so, our
objectives were to promote standardization of feasibility methods;
encourage collaboration among investigators and sponsors work-
ing in this area; demonstrate the value of feasibility data
publication; and avoid the development of redundant studies.
The online database derived from the data identiﬁed in this review
is intended to support the efﬁcient and effective adoption of
mobile technologies in clinical research by creating a single,
searchable, up-to-date resource that gives users easy access to
existing knowledge. The objectives of this paper are therefore to
describe the methodology of our systematic scoping review,
summarize key trends that emerged from the identiﬁed studies,
and discuss future directions for maintenance of an online
database of feasibility studies designed to advance the science
and ultimately the adoption of mobile endpoints.
RESULTS
Screening
Our initial search retrieved 3466 references (see Fig. 1). We
excluded over half of the retrieved references (n= 2186) after title
screening, and abstract screening eliminated a further 63% (n=
802). The majority of excluded publications were either not
conducted in a deﬁned therapeutic area, or not conducted in a
deﬁned participant population. A total of 478 publications were
included in the full text review, during which we excluded 203
publications on the basis of our inclusion criteria. Data were
extracted from the remaining 275 publications.
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Search 1/1/2014 – 5/31/2018
(n=3,488)
Out of scope articles excluded (n=22)
• 3 not in English
• 13 books/book chapters
• 5 studies conducted in developing countries
• 1 published in 2013
Titles screened 
(n=3,466)
Duplicates or irrelevant titles excluded
(n=2,186)
Abstracts screened 
(n=1,280)
Abstracts excluded (n=802)
• 257 not conducted in therapeutic area
• 216 not conducted on a defined participant
population
• 77 did not include mobile technology/did not
specify technology used
• 73 used the mobile technology as a therapeutic
intervention without capturing any outcomes data
• 81 data captures clinical setting only
• 44 methods papers/meta-analyses or systematic
reviews
• 32 were not feasibility studies
• 14 case studies/computer simulations/editorials
• 8 did not capture objective outcomes data
Full-text articles assessed for 
eligibility
(n=478)
Full-text articles excluded (n=203)
• 51 not conducted in therapeutic area
• 49 not conducted on a defined participant
population
• 41 data capture clinical setting only
• 24 relied on clinician for data capture
• 9 methods papers/meta-analyses or
systematic review
• 8 were not feasibility studies
• 6 did not include mobile technology/did not
specify technology used
• 6 used mobile technology as an intervention
• 5 did not capture objectives outcomes data
• 4 case studies/computer simulations
Articles included in data extraction 
(n=275)
Fig. 1 Preferred reporting items for systematic reviews and meta-analyses (PRISMA) ﬂow diagram
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Data categorization
Just over half of all included studies were in neurology or
musculoskeletal therapeutic areas, with pulmonary, sleep, endo-
crine, cardiovascular, and pediatrics making up another 30%
combined. Algorithm development was the most common
objective (236 studies), followed by sensor performance (133 stu-
dies), operational feasibility (126 studies), and software develop-
ment (24 studies). The median number of participants per study
was n= 33 (range 1–625), with larger samples evident in studies
focused on cardiology, neurology, and musculoskeletal disorders.
Two “n-of-1’’ studies11 were identiﬁed (one in nephrology, one in
neurology).
Some studies used more than one research tool, such that the
275 studies included 321 technologies. Sixty-seven percent of the
technologies were wearable sensors, such as actigraphy, smart-
watches, smart-clothing, chest-straps, adhesive patches, and
Holter monitors. The remaining tools included tablets and
smartphones, implanted sensors such as continuous glucose
monitors, and cameras. We did not identify any studies using
ingestible sensors. Tablets and smartphones were used in a variety
of ways; for example, data captured passively via the embedded
accelerometer, and active data capture via an app such as ﬁnger-
tapping or psychomotor vigilance tasks. Within each of these
categories, a wide array of make/model tools were studied, each
differing in terms of their sampling frequency, ﬁltering, data
processing, and compatible software programs.
In some cases, missing data precluded a full understanding of
some studies and this would likely impact reproducibility.
Important gaps include the software used for analysis (73%
complete), the comparator measure (83% complete), the make
and model of the technology (93% complete), and the age and
gender of participants (91% and 85%, respectively). All papers
reported the number of participants and the type of technology
used, although there was substantial variation in the way that
sensors were listed in each paper (for example, “motion sensor’’,
“accelerometer’’, “tri-axial accelerometer’’). Several papers listed a
non-speciﬁc term such as “pedometer’’ without specifying the
actual sensors contained within. Rather than attempt to impose an
interpretation, our database lists the technology as reported
within the source publication.
A static database of all extracted data is accessible via Table e2
(online supplement) with full study references including a digital
object identiﬁer (DOI); however, we encourage readers to access
the online version that will be updated regularly as more studies
emerge (http://feasibility-studies.ctti-clinicaltrials.org). The current
layout and features of the online database are shown in Fig. 2. In
addition, the papers that we excluded are listed in Table e3. The
online version of the database can be ﬁltered and searched
electronically, enabling a user to ﬁnd information most relevant to
their work.
DISCUSSION
In this paper, we describe the methodology underlying our
systematic scoping review of feasibility studies focused on mobile
technologies. We also summarize key trends that emerged when
compiling our searchable database, such as the fact that although
some tools we identiﬁed (such as Holter monitors and actigraphy)
have been used in research and clinical settings for decades, other
tools (such as smart-clothing and adhesive patches) are more
recent developments, emphasizing that there is still much to learn
about different methods of deploying mobile sensors. We noted
an absence of standards in both the use of mobile technology in
research as well as reporting methodology, evidenced by the lack
of consistency across publications, which made data extraction
challenging. The development of methodology and reporting
standards, although beyond the scope of our current project,
would be extremely beneﬁcial for the ﬁeld. The scope and content
of our database demonstrates that the deployment of mobile
technology in research is an active, growing area of interest to
investigators. Information gleaned from our database can not only
be used by sponsors to inform trial design, but may also be useful
to regulatory bodies such as the FDA, technology manufacturers,
engineers and data scientists, patient groups, institutional review
boards and ethics panels, statisticians, health policy planners, and
clinicians. Further, the ability to access data from feasibility studies
readily is likely to facilitate incorporation of mobile endpoints into
settings other than clinical trials, such as observational or
interventional health outcomes studies,12 translational research,13
and eventually, clinical care.14
Fig. 2 A screenshot of the online database depicting the current layout and features
J.P. Bakker et al.
3
Scripps Research Translational Institute npj Digital Medicine (2019)    47 
Although speciﬁc objectives differed across the publications we
identiﬁed, in general all studies aimed to determine whether a
speciﬁc technology and/or outcome assessment was “ﬁt for
purpose”; that is, whether the system was capable of generating
the necessary data in a stated context of use. Many studies
addressed one or both of the following sets of questions: (A) what
physical construct is intended to be measured (e.g., movement),
what sensor is required to capture those data (e.g., an
accelerometer), and how accurate are the sampled data (e.g.,
intra- and inter-sensor variability of the acceleration signal when
compared against a mechanical shaker with known acceleration);
and/or (B) how are the data converted to a meaningful endpoint
(e.g., development of an algorithm that converts an acceleration
signal into an estimate of total sleep time) and how does the
endpoint perform against a comparator (e.g., the agreement
between algorithm-generated sleep data with polysomnography-
generated sleep data)? The former set of questions address the
concept of veriﬁcation and relate to intrinsic capabilities of the
sensor, whereas the latter address the concept of validation and
relate to the application of sensor-derived data to health concepts
in human participants. A more thorough explanation of these
concepts is included in the CTTI “Advancing the Use of Mobile
Technologies for Data Capture and Improved Clinical Trials”
recommendations (https://www.ctti-clinicaltrials.org/sites/www.
ctti-clinicaltrials.org/ﬁles/mobile-devices-recommendations.pdf).
Other feasibility studies in our dataset addressed considerations
such as ease of use, participant comfort, security and integrity of
data transfer or storage, and software development.
We did not attempt to create data ﬁelds indicating study quality
or exclude papers that did not achieve a certain quality threshold
for several reasons. Firstly, there is tension between study quality
and reporting quality,15 and we were only in a position to evaluate
what has been reported. Secondly, we concluded that all of the
data we sought to extract were valuable, and that highlighting
missing data and variability in reporting would provide an
opportunity for investigators in the ﬁeld to reﬂect on these issues
when preparing future manuscripts. Thirdly, the study quality
assessments typically used in other systematic reviews may not be
appropriate for feasibility studies. For example, in an algorithm
development study aiming to capture steps, the sample size is the
number of steps, not the number of participants, although larger
participant sample sizes remain important to capture variability
and ensure generalizability.7,8 In our opinion, it is beneﬁcial to
focus on whether a particular feasibility study is useful, rather than
whether it is of sufﬁcient quality, although there is likely a wide
overlap across these concepts. To that end, we recommend the
development of levels of evidence, which may help deﬁne what is
reported in feasibility studies and will therefore make them more
useful to others in the ﬁeld. Thus, in the absence of methodo-
logical and reporting standards, we leave it to end-users to
explore the database and compare and contrast what they see
with “best practices’’ as outlined in the CTTI Mobile Technology
recommendations (https://www.ctti-clinicaltrials.org/projects/
mobile-technologies).
One noteworthy area of missing data was the absence of
thorough descriptive information regarding study participants. We
aimed to capture only what would be considered the most basic
demographic information—age and gender/sex—and noted that
these variables were missing in 9% and 15% of publications,
respectively. Many of the publications in our database were
published in journals that typically have an engineering focus;
however, all involved data collection in human participants.
Although we do not have quantitative data available as we did not
aim to extract it, we can attest that many publications captured in
our search did not report important participant characteristics
such as race/ethnicity, measurements of body habitus, measure-
ments of socioeconomic status, or descriptions of disease severity.
The use of mobile technology in clinical studies, particularly those
adopting a “bring your own device’’ model, may impose barriers
to participation in underrepresented/underserved populations,
and therefore we encourage investigators to assess and report the
sociodemographic characteristics of study participants, and
consider issues of equity and equality during the study
design phase.
There are some limitations to our approach that should be
noted. Bias may have been introduced by missing relevant
literature, given our choice of PubMed as the bibliographic
database to search, search terms, and inclusion criteria, particu-
larly given the inconsistencies in terminology across papers. In
particular, it is possible that Layer #1 in Table e1, which ensures
that a publication refers to some kind of sensor that can be
attached to a human participant, may have a slight bias towards
technical/engineering authors who may refer to the underlying
technology, as opposed to more clinically focused authors who
might in some cases use a single term such as a manufacturer
name, a device name, or a generic term such as “activity monitor”
for wearable technology containing an accelerometer. We
attempted to investigate other sources of bias in our search
terms; for example, we performed a sensitivity analysis whereby
the word “pilot’’ was removed from our search terms, and found
that fewer than 5% of eligible publications were missed by doing
so. Some methodological decisions may have resulted in the
exclusion of papers outside of our scope that some readers might
ﬁnd particularly useful, such as studies conducted entirely in an
inpatient or clinical setting, or those published before 2014. Our
decision to limit the search to publications from 2014 onwards
was because our aim was to assemble a resource that reﬂects the
current state of the art. The contents of the database are limited to
those feasibility studies published in the peer-reviewed literature,
and we acknowledge that relevant data may also exist in the gray
literature, in conference proceedings, or in internal reports used
by investigators to inform their own future studies and therefore
not published at all. In the future, we hope to develop
functionality for the online database so that users can put forward
potentially relevant publications that we have missed, as well as
unpublished reports.
The use of mobile technologies for data capture is an evolving
and rapidly expanding ﬁeld. CTTI plans to update the literature
search annually. This process may require changes to our search
terms and data extraction methodology as technology progresses.
On a quarterly basis, we will also examine relevant publications
that we receive from users of the database that we had missed, to
see how our search terms or inclusion criteria might be modiﬁed
to capture similar publications in the future. Our hope is that the
growing interest in this ﬁeld as well as the demonstrated success
of using mobile technology in clinical research, will lead to a more
standardized lexicon, as well as relevant medical subject headings
(MeSH terms, https://meshb.nlm.nih.gov/) terms that could be
assigned to eligible publications, making it easier to ﬁnd them in
future searches. Eventually, if investigators in the ﬁeld ﬁnd the
online resource useful, journals could encourage or require that
authors include all data ﬁelds and upload their manuscript to the
database, akin to the registration and reporting of clinical trials.
Although beyond the scope of the current work, a registry would
allow for linking different studies and trials that have adopted the
same technology, as well as providing information as to the
successful use of mobile technologies in drug approval and/or use
in clinical practice.
In conclusion, we have created a freely accessible, online
database of feasibility studies assessing the use of mobile
technologies for data capture, intended to be a valuable resource
for many stakeholder groups, including researchers, ethicists,
regulatory bodies, and patient groups. One of our objectives was
to create a user-friendly database that investigators in the ﬁeld
can explore as they make decisions regarding which technology
would be most useful for a particular research study, although it
J.P. Bakker et al.
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should be emphasized that clinical relevance is only one part of
the decision-making criteria. The CTTI Mobile Technology
recommendations provide information on other important topics
to consider beyond sensor veriﬁcation and algorithm validation,
such as cyber security, patient preferences, and data rights
(https://www.ctti-clinicaltrials.org/programs/mobile-clinical-trials).
We hope that the online database resulting from our systematic
scoping review reported here becomes a widely used tool,
thereby promoting standardization of methodology and report-
ing, and contributing to the design and implementation of high-
quality, efﬁcient trials.
METHODS
Conduct of the systematic scoping review
On 21 June 2018, CTTI conducted a systematic search of peer-reviewed
literature indexed in PubMed and published between January 2014 and
May 2018. We did not restrict the scope of our search to any single
therapeutic area or mobile technology. A multi-stakeholder team of
clinical, academic, technical, operational, and patient experts developed
the search terms (listed in Supplementary Table 1 of the online
supplement), inclusion criteria (Table 1), and selection of data to be
extracted from the ﬁnal publications (Table 2). A medical librarian
supported the development of the search terms.
Table 1. Inclusion criteria adopted to enable the identiﬁcation of suitable feasibility studies
Pre-review Reported results of original data collection (for example, meta-analyses, editorials, letters, opinion pieces, and methods papers were
excluded).
Population Collected data from human participants (for example, studies that reported results of a computer simulation were excluded).
Stated a speciﬁc therapeutic area.
Deﬁned a participant population that either:
a. Included participants from the target population or;
b. Included participants that would be generalizable to the target population.
Intervention Included at least one mobile technology meeting our deﬁnition for objective outcome (efﬁcacy or safety) data capture.
Deﬁned the speciﬁc technology used.
Comparator Speciﬁed a comparator (sensor performance and algorithm development studies only).
Outcome Evaluated mobile technology/ies capturing objective outcomes data (for example, studies examining as the primary technology were
excluded).
When mobile technology/ies were used as a therapeutic intervention, the study reported outcomes data.
Study design Described a feasibility study in line with our deﬁnition; speciﬁcally, a feasibility study addresses one or more of the following
components:
a. Performance of an outcome of interest against a comparator where the outcome of interest could be related to:
i. Measurement performance of sensor and/or;
ii. Algorithm performance (clinical endpoints);
b. Human factors considerations (acceptability, tolerability and usability);
c. Participant adherence;
d. Completeness of data.
Captured data outside of a clinical setting or captured data in an inpatient or clinic setting speciﬁcally to enable out-of-clinic use.
Reported data from a participant sample (for example, case studies were excluded; however, n-of-1 studies12 were considered in
scope).
Country of origin is reported to have “high’’ or “very high’’ human development by the United Nations Human Development Index,
http://hdr.undp.org/en/composite/HDI.
ePRO electronic patient-reported outcome
Table 2. Data ﬁelds extracted from identiﬁed feasibility studies
Field Deﬁnition Allowed values
Title Free text
Authors Last name, initials Free text
Journal Name Free text
Year 2014, 2015, 2016, 2017, 2018
DOI Digital object identiﬁer. A unique alphanumeric string used
to identify content and provide a persistent link to the
manuscript’s online location.
Free text
Category The type of study according to the authors’ objectives. Sensor performance, algorithm development, operational
feasibility, software development
Therapeutic area A knowledge ﬁeld that focuses on research and
development of treatments for diseases and pathologic
ﬁndings, as well as prevention of conditions that negatively
impact the health of an individual.
Selected from a list of FDA-approved drugs by therapeutic
area, https://www.centerwatch.com/drug-information/fda-
approved-drugs/therapeutic-areas, with “pre-natal’’
included as an additional therapeutic area.
Medical condition An abnormal state of health that interferes with normal or
regular feelings of wellbeing.
Free text
J.P. Bakker et al.
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Following the PubMed search, we conducted a multi-step review
process to select publications for inclusion. First, two of four trained
analysts (A.B., E.B., C.M., K.W.) independently reviewed each publication
title against the inclusion criteria, following the PICOS16 (Population,
intervention, comparison, outcome; study design) framework. Second, two
of the four analysts reviewed the abstracts of the remaining, potentially
eligible publications to determine whether each met our inclusion criteria.
When there was disagreement between two reviewers during either
phase, the decision whether to advance a publication was resolved by a
third analyst. Finally, two analysts reviewed the full text of each of the
publications that passed the abstract screening stage, with a third used to
settle any disagreements and establish the ﬁnal list of publications for
inclusion.
To build the database, four analysts (A.B., E.B., C.M., K.W.) extracted the
data and categorized each publication as described in Table 2. Each
publication was assigned to one or more of the following categories:
sensor performance; algorithm development; operational feasibility; and
software development. The following data were extracted from each:
medical condition (used to identify therapeutic area); concepts of interest
captured by the mobile technology (for example, sleep); speciﬁc outcomes
captured by the digital measurement (for example, total sleep time);
comparator used to assess the digital measurement (for example,
polysomnography); information relating to the sensor/s (for example,
accelerometry and photoplethysmography); details related to the algo-
rithms or software (if applicable); and descriptive data for the study
sample. After the data were extracted from each publication, it was
standardized by two analysts (J.G. and C.M.).
Reporting Summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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